Boston Scientific Corporation (BSX)
After hours:
| Previous close | 74.26 |
| Open | 74.50 |
| Bid | 74.84 x 900 |
| Ask | 75.48 x 1200 |
| Day's range | 74.42 - 75.67 |
| 52-week range | 48.35 - 79.43 |
| Volume | |
| Avg. volume | 5,918,322 |
| Market cap | 110.146B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 60.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Boston Scientific Announces Results for Second Quarter 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 fo
- PR Newswire
Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 24 prior to the conference call.
- GlobeNewswire
Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific
Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (“Boston Scientific”) (NYSE: BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity valu
